Company Description
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States.
The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia.
It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for the treatment of major depressive disorder and acute stress reaction/acute stress disorder; TNX-1300, a double-mutant cocaine esterase for the treatment of cocaine intoxication; TNX-1500, an Fc-modified humanized monoclonal antibody to prevent kidney transplant rejection, as well as to treat autoimmune conditions; TNX-4800, a humanized monoclonal antibody for the seasonal prevention of Lyme disease; and TNX-2900, an intranasal oxytocin potentiated with magnesium for the treatment of Prader-Willi syndrome.
Further, it is developing TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, and arginine-vasopressin deficiency; TNX-801, a live horsepox vaccine for the prevention of smallpox and mpox; TNX-4200, a small molecule broad-spectrum antiviral agent targeting CD45 for the treatment or prevention of viral disease; TNX-4900, a highly selective small-molecule Sigma-1 receptor antagonist for neuropathic pain; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; and TNX-1800 and TNX-1850, live modified horsepox vaccines for the prevention of COVID.
Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in Berkeley Heights, New Jersey.
| Country | United States |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 142 |
| CEO | Seth Lederman |
Contact Details
Address: 200 Connell Drive, Suite 3100 Berkeley Heights, New Jersey 07928 United States | |
| Phone | 862 799 8599 |
| Website | tonixpharma.com |
Stock Details
| Ticker Symbol | TNXP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001430306 |
| CUSIP Number | 890260839 |
| ISIN Number | US8902608392 |
| Employer ID | 26-1434750 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Seth Lederman M.D. | Co-Founder, President, Chief Executive Officer and Chairman |
| Mrs. Jessica Edgar Morris | Chief Operating Officer |
| Dr. Gregory M. Sullivan M.D. | Chief Medical Officer and Secretary |
| Irina Ishak | General Counsel |
| Dr. Darryl Rideout Ph.D. | Executive Vice President of Experimental Chemistry |
| Dr. Sina Bavari Ph.D. | Executive Vice President of Infectious Disease Research and Development |
| Dr. Zeil Rosenberg M.D., M.P.H. | Executive Vice President of Medical |
| Thomas Englese M.B.A. | Executive Vice President of Commercial Operations |
| Ganesh Kamath | Head of Market Access |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 31, 2026 | 8-K | Current Report |
| Mar 30, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 27, 2026 | SCHEDULE 13G/A | Filing |
| Mar 26, 2026 | 8-K | Current Report |
| Mar 20, 2026 | PRE 14A | Other preliminary proxy statements |
| Mar 18, 2026 | 8-K | Current Report |
| Mar 13, 2026 | ARS | Filing |
| Mar 13, 2026 | 8-K | Current Report |
| Mar 12, 2026 | 10-K | Annual Report |
| Mar 10, 2026 | 8-K | Current Report |